News Conference News ESC Heart Failure 2022 Dapagliflozin Boosts Health Status Across LVEF Range Shelley Wood May 23, 2022
News Daily News FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy Michael O'Riordan April 29, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Daily News More Evidence Links Breast Arterial Calcification and CVD Risk L.A. McKeown March 15, 2022
News Daily News In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report Michael O'Riordan January 27, 2022
News Conference News AHA 2021 Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF Michael O'Riordan November 19, 2021
News Conference News AHA 2021 Canagliflozin Improves Quality of Life in HF Patients Michael O'Riordan November 16, 2021
News Daily News As Amyloidosis Field Explodes, Physicians Need to Spot and Treat Todd Neale October 20, 2021
News Daily News HFSA 2021 In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity Michael O'Riordan September 15, 2021
News Conference News HFSA 2021 PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF Todd Neale September 13, 2021
News Daily News Milrinone, Dobutamine Comparable for Cardiogenic Shock: DOREMI Todd Neale August 10, 2021
News Conference News HRS 2021 STROKE-VT: DOACs Cut Cerebrovascular Events After LV Arrhythmia Ablation Todd Neale July 29, 2021
News Daily News AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More Shelley Wood December 17, 2020
News Daily News Could Statins Curb Fatal or Severe COVID-19? Some Clues Michael O'Riordan August 14, 2020
News Features COVID-19’s Enduring Impact on the Heart? Some Clues and Predictions Shelley Wood July 20, 2020
News Daily News Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects Michael O'Riordan July 13, 2020
News Daily News Cardiac Considerations Amid COVID-19: Shared Stories May Save Lives L.A. McKeown March 25, 2020
News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020